Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company at the forefront of developing innovative viral-based immunotherapies to combat cancer. Headquartered in Massachusetts, the company leverages its proprietary multimodal platforms to deliver off-the-shelf therapies that elicit a robust and individualized systemic anti-tumor immune response. Operating within the competitive and rapidly evolving immuno-oncology space, Candel Therapeutics addresses significant unmet medical needs by targeting solid tumors with precision and innovation.
Core Technologies and Platforms
Candel Therapeutics has established two proprietary viral-based immunotherapy platforms designed to revolutionize cancer treatment:
- Gene Mediated Cytotoxic Immunotherapy (GMCI™) Platform: This platform utilizes genetically modified adenoviruses to deliver a localized, tumor-targeted immune response. As an "off-the-shelf" solution, GMCI™ activates the patient’s immune system to generate a personalized and precise response against cancer cells without requiring extensive customization.
- enLIGHTEN™ Discovery Platform: A systematic, iterative platform leveraging herpes simplex virus (HSV) constructs and advanced analytics to create novel viral immunotherapies. This platform is designed to accelerate the discovery and development of therapies for solid tumors, utilizing human biology insights to optimize therapeutic outcomes.
Pipeline and Key Product Candidates
Candel’s product pipeline is anchored by two lead candidates:
- CAN-2409: Developed from the adenovirus platform, this candidate is undergoing clinical trials for multiple indications, including non-small cell lung cancer (NSCLC), borderline resectable pancreatic ductal adenocarcinoma (PDAC), and localized prostate cancer. CAN-2409 aims to address patients who are non-responsive to traditional immune checkpoint inhibitors, providing a novel therapeutic option.
- CAN-3110: Originating from the HSV platform, this candidate is being evaluated in phase 1b trials for recurrent high-grade glioma (rHGG). Designed to treat difficult-to-treat cancers, CAN-3110 demonstrates the potential of HSV-based therapies in addressing aggressive tumor types.
Market Position and Competitive Landscape
Operating within the immuno-oncology sector, Candel Therapeutics competes against established biopharmaceutical giants and emerging innovators. The company differentiates itself through its multimodal approach, combining the benefits of viral-based platforms with advanced analytics and human biology insights. This unique positioning allows Candel to address complex cancers with tailored, systemic solutions that complement existing therapies.
Significance and Industry Impact
Candel Therapeutics’ commitment to developing off-the-shelf, multimodal immunotherapies positions it as a key player in the fight against cancer. By focusing on systemic, individualized immune responses, the company addresses critical gaps in current treatment paradigms. Its innovative platforms and promising clinical results underscore its potential to transform cancer care, making it a noteworthy entity in the biopharmaceutical industry.
Candel Therapeutics, Inc. (Nasdaq: CADL) has appointed Francesca Barone, M.D., Ph.D., as its new Chief Scientific Officer. With over 20 years of expertise in immunology and drug development, Dr. Barone previously served as Candel's Vice President, Head of Research. She has substantial experience from her roles at Kintai Therapeutics and Senda Biosciences. Dr. Barone expressed optimism about the company's investigational immunotherapies aimed at treating cancer, emphasizing their unique ability to induce strong immune responses. This leadership change aims to enhance Candel's clinical development efforts.
Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company specializing in oncolytic viral immunotherapies, announced upcoming presentations at two virtual investor conferences in January 2022. Paul Peter Tak, CEO, will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, with on-demand viewing starting at 7:00 am ET. He will also present live at the B. Riley Securities’ 2022 Oncology Conference on January 28, 2022, at 11:30 am ET. The company focuses on advancing cancer treatments through innovative engineered viruses.
Bionaut Labs and Candel Therapeutics have formed a strategic collaboration to advance preclinical development of remote-controlled microscale robots for targeted delivery of oncolytic viral immunotherapies to brain tumors. Utilizing Bionaut’s precision medicine technology, the partnership aims to enhance therapeutic efficacy for high-grade glioma patients. Both companies will retain rights to their platforms while working together towards clinical trials. Terms of the agreement remain undisclosed.
Candel Therapeutics (Nasdaq: CADL) announced a collaboration with the Partnership for Accelerating Cancer Therapies (PACT) for a biomarker analysis in a phase 2 clinical trial targeting non-small cell lung cancer (NSCLC). The study will evaluate the efficacy of CAN-2409 combined with immune checkpoint inhibitors following inadequate responses to initial treatments. With three patient cohorts, the collaboration aims to identify early biological indicators of treatment response. This partnership enhances Candel's research credibility and aims to advance therapeutic options for cancer patients.
Candel Therapeutics (Nasdaq: CADL) presented encouraging data from its phase 1 trial of CAN-3110 at the SITC Annual Meeting. This oncolytic virus therapy showed significant T-cell infiltration and immune activation in patients with recurrent high-grade glioma. Preliminary data previously reported at ASCO indicated an overall survival of 11.7 months. The histological analysis confirmed persistence of viral antigens and a strong immune response, suggesting the potential of CAN-3110 to improve treatment outcomes for patients with this challenging cancer.
Candel Therapeutics (Nasdaq: CADL) reported its Q3 financial results, announcing a net loss of $16.2 million for the quarter, a substantial increase from $2.6 million in Q3 2020. Cash reserves as of September 30, 2021, stood at $88.4 million, bolstered by an IPO in August 2021. Research and development expenses surged to $5.3 million from $1.8 million year-over-year, attributed to increased clinical trial activities. The company remains on track to fund operations into Q2 2023, with several clinical presentations highlighting advancements in its oncolytic viral therapies, CAN-2409 and CAN-3110.
On November 2, 2021, Candel Therapeutics, Inc. (Nasdaq: CADL) announced that CEO Paul Peter Tak will speak at several investor conferences in November.
- Credit Suisse 30th Annual Healthcare Conference: Fireside Chat on November 8, 2021, at 11:20 am ET.
- BMO Biopharma Spotlight Series: Panel Discussion on November 8, 2021, at 12:45 pm ET.
- Jefferies London Healthcare Conference: Fireside Chat on November 17, 2021, at 1:00 pm GMT.
For more information and webcasts, visit Candel's website.
Candel Therapeutics (Nasdaq: CADL) announced its participation in key medical conferences, including the 13th International Oncolytic Virus Conference and the 26th Annual Meeting of the Society for Neuro-Oncology. Presentations will focus on their oncolytic viral immunotherapies, CAN-3110 and CAN-2409, with insights into their trial data. Notably, CAN-2409 targets high-grade gliomas and shows promise in combination therapies. The events are scheduled for November 5, 6, and 19, 2021, with additional details available on Candel's website.
Candel Therapeutics (Nasdaq: CADL) presented tolerability data from its phase 3 clinical trial of CAN-2409 for localized prostate cancer at the 28th Annual Prostate Cancer Foundation Scientific Retreat on October 28, 2021. The trial involved 745 patients, with over 2,000 injection procedures performed. Results showed 65% of patients found transperineal injections equally or better tolerated than biopsies, while 89% reported the same for transrectal injections. Overall, 100% felt positive about their participation. This supports the treatment's promise, potentially improving outcomes while reducing the need for long-term androgen deprivation therapy.
Candel Therapeutics (Nasdaq: CADL) appointed Dr. Mace L. Rothenberg as a senior advisor to CEO Paul Peter Tak. Dr. Rothenberg, a seasoned medical executive with over 30 years in government and industry, previously served as Chief Medical Officer at Pfizer, where he played a crucial role in the development of several cancer therapies and the COVID-19 vaccine. His expertise is expected to support Candel's growth and enhance its oncology drug pipeline, particularly in advancing their lead candidates, CAN-2409 and CAN-3110, through clinical trials.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
What does Candel Therapeutics, Inc. specialize in?
What are Candel Therapeutics’ key platforms?
What are the lead product candidates in Candel’s pipeline?
How does Candel differentiate itself in the immuno-oncology market?
What challenges does Candel Therapeutics face?
What is the significance of Candel’s GMCI™ platform?
What is the enLIGHTEN™ Discovery Platform?
What types of cancers does Candel Therapeutics target?
What is the business model of Candel Therapeutics?
How does Candel’s approach complement existing cancer therapies?
